Expanding the Landscape of TPD: E3-Agnostic Approach to Unlock the E3 Ligase Space
- Establishing a high‑throughput, phenotype‑driven platform that enables rational E3 ligase selection and uncovers ligases not previously leveraged in TPD to expand degrader design possibilities
- Demonstrating how diverse DOS‑derived chemical scaffolds and ligase deconvolution workflows identify and optimize novel E3 ligase binders for both bifunctional degraders and molecular glue applications
- Leveraging ligases with low bone‑marrow expression to advance safer, orally bioavailable TPD therapeutics with improved selectivity, reduced myelotoxicity, and broad target applicability